ANKYRA
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments. Systemic dosing of these potent immune stimulants is restricted due to widespread immune activation and toxicity. When cytokines are injected into tumor tissue, they localize specifically and persistently, causing intense hot spots of inflammation that activate an anti-tumor immune response. Ankyra used its Anchored Immunotherapy Platform to develop ANK-101, a stable complex of a modified IL-12 cytokine with al... uminum hydroxide (Alhydrogel) to overcome the limitations of traditional cytokine therapeutics. Alhydrogel, an FDA-approved adjuvant for use in human and veterinary vaccines, acts as a scaffold to locally retain the potent activity of IL-12 after intratumoral administration, improving its therapeutic window. Ankyra's mission is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.
ANKYRA
Social Links:
Industry:
Biotechnology Oncology
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ankyratx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
59.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Mobile Non Scaleable Content Sitelinks Search Box Yoast WordPress SEO Plugin Yoast Plugins
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
HEPHAISTOS-Pharma
HEPHAISTOS-Pharma is a biotechnology startup developing anti-tumor immunotherapies.
Kumquat Biosciences
Kumquat Biosciences is a biotech company developing therapies to discover oncology medicines.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sands Capital Ventures
Sands Capital Ventures investment in Series B - Ankyra
Google Ventures
Google Ventures investment in Series B - Ankyra
Borealis Ventures
Borealis Ventures investment in Series B - Ankyra
Mithril Capital Management
Mithril Capital Management investment in Series B - Ankyra
Fidelity
Fidelity investment in Series B - Ankyra
Polaris Partners
Polaris Partners investment in Series B - Ankyra
Spring Mountain Capital
Spring Mountain Capital investment in Series B - Ankyra
Polaris Partners
Polaris Partners investment in Seed Round - Ankyra
Key Employee Changes
Official Site Inspections
http://www.ankyratx.com Semrush global rank: 9.44 M Semrush visits lastest month: 386
- Host name: 132.129.223.35.bc.googleusercontent.com
- IP address: 35.223.129.132
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Ankyra"
Home - Ankyra Therapeutics
Anchored Immunotherapy. We are a clinical-stage biotech developing anchored-drug conjugates to trigger long lasting anti-tumor response without compromising safety.See details»
Ankyra - Crunchbase Company Profile & Funding
Contact Email [email protected] Ankyra is a biotech company developing anchored immunotherapy for cancer treatments. Systemic dosing of these potent immune stimulants is restricted due to widespread immune activation and …See details»
Our Patients - Ankyra - ankyratx.com
Leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Improving the lives …See details»
Who We Are - Ankyra - ankyratx.com
Dianne Brennick serves as the Associate Director, Human Resources where she leads all aspects of Ankyra’s Human Resources function. With over 12 years of Human Resources experience, …See details»
Ankyra Therapeutics - LinkedIn
Ankyra Therapeutics | 1,823 followers on LinkedIn. Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response | Ankyra is developing a novel approach ...See details»
GEO Accession viewer - National Center for Biotechnology …
Oct 17, 2023 [email protected]: Organization name: ANKYRA Therapeutics: Street address: 245 Main St, 2nd Floor: City: Cambridge: State/province: MA: ZIP/Postal code: …See details»
Ankyra Announces Appointment of Dr. Julia Butchko and Ms
Sep 23, 2024 Ankyra was founded in 2019 and is headquartered in Cambridge, Massachusetts. For more information, please visit www.ankyratx.com. Contacts. For Investor Inquiries: …See details»
Ankyra Therapeutics - VentureRadar
Similar Companies: IO Biotech Denmark Privately Held IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of …See details»
Ankyra Therapeutics Receives FDA IND and Health …
Oct 24, 2023 For more information, please visit www.ankyratx.com. Contacts. For Investor Inquiries: Howard L. Kaufman, MD President and CEO Ankyra Therapeutics [email protected].See details»
Ankyra Therapeutics - Overview, News & Similar companies
Mar 4, 2024 Who is Ankyra Therapeutics. Founded in 2019 and based in Boston, Ankyra has developed a platform for specific immunotherapies for cancer. Ankyra developed methods to …See details»
Ankyra Therapeutics Announces $45 Million Series B Financing and ...
Nov 12, 2021 For Investor Inquiries: Tillman Gerngross, Executive Chairman Ankyra Therapeutics [email protected] For Media Inquiries: Noah Oshry Head of Business …See details»
Corporate Responsibility - Ankyra - ankyratx.com
At Ankyra Therapeutics, we are committed to environmental responsibility and sustainability. We recognize the importance of protecting our planet and are dedicated to integrating …See details»
Ankyra Therapeutics Announces Collaboration to Evaluate ANK …
Feb 7, 2023 For more information, please visit www.ankyratx.com. *Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement. Contacts. For Investor Inquiries: ...See details»
Ankyra Therapeutics Appoints Robert V. Tighe, an ... - Business Wire
Aug 7, 2023 For more information, please visit www.ankyratx.com. Contacts. For Investor Inquiries: Howard L. Kaufman President and CEO [email protected]. For Media …See details»
Ankyra Therapeutics Announces First Visceral Tumor Patient …
Nov 5, 2024 Ankyra’s lead program ANK-101, IL-12 anchored to aluminum hydroxide, has potential to treat a broad range of cancers. For more information, please visit …See details»
Ankyra Therapeutics Announces Research Collaboration with the …
Jun 3, 2022 For more information, please visit www.ankyratx.com. Contacts. For Investor Inquiries: Howard L. Kaufman, MD President and CEO Ankyra Therapeutics [email protected].See details»
Press Releases - Ankyra Therapeutics
Jun 1, 2024 Oct 12, 2023 | European Organization for Research and Treatment of Cancer (EORTC):Preclinical pharmacokinetic (PK) and tumour growth inhibition (TGI) modelling for …See details»
GEO Accession viewer - National Center for Biotechnology …
Status: Public on Oct 17, 2023: Title: Intratumoral aluminum hydroxide-anchored IL-12 drives potent anti-tumor activity by remodeling the tumor microenvironmentSee details»
Our Approach - Ankyra - ankyratx.com
Despite efforts to develop tumor- targeting therapies, very few are focusing on keeping drugs in the tumor microenvironment once they are there.See details»
Our Pipeline - Ankyra - ankyratx.com
IL-12 bound to the anchor, aluminum hydroxide (Alhydrogel®) Retained at the tumor site > 28 days in preclinical models; Potent single-dosing therapeutic activity as a monotherapy and in …See details»